Smith & Nephew plc (SNN) Stock Price & How to Invest
Last updated November 2026
Short answer
Smith & Nephew is a British medical technology company selling hip and knee implants, arthroscopy and sports medicine systems, and advanced wound dressings, on roughly $6.3 billion of revenue for the twelve months to June 27, 2026. The share unit is what screeners get wrong: SNN on the NYSE is an American Depositary Share representing TWO ordinary shares of the London-listed company (ticker SN), so per-share figures taken from the UK line need doubling before they meet the $30 quote. A second quirk cuts the other way: despite being incorporated in England, the company reports in US dollars, so there is no currency translation to undo. As of November 20, 2026 the ADS closed at ~$30.06, down ~8.6% year to date and ~6.0% over one year, for a market cap of ~$12.6 billion and a dividend yield near 2.7%. In its November third-quarter update the company cut 2026 guidance a second time and said talks with Johnson & Johnson over a combination involving DePuy Synthes had ended, with strategic alternatives for Orthopaedics still under review.
SNN stock price
As of 2026-11-20, Smith & Nephew plc (SNN) last closed at $29.83, down 9.6% over the past year. Over the past 52 weeks it has traded between $26.42 and $36.90.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Smith & Nephew plc's investor relations page. Walnut is informational, not investment advice.
SNN key stats
At $29.83 on November 20, 2026, Smith & Nephew plc (SNN) has a market cap of $12.5B, a P/E of 20.3 on trailing earnings (12.6 on forward earnings) and a dividend yield of 2.65%.
- Market cap
- $12.5B
- P/E (trailing)
- 20.3
- P/E (forward)
- 12.6
- EPS (trailing 12 months)
- $1.47
- Price to book
- 12.3
- Dividend yield
- 2.65%
- Beta
- 0.67
Market cap, P/E and yield are measured at the $29.83 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Smith & Nephew plc (SNN)?
The last two weeks for Smith & Nephew plc, as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- SNN closed at $29.83 on November 20, 2026, down 4.6% over the past five trading days (from $31.28).
- On November 18, 2026, Smith & Nephew plc filed a current report (6-K) with the SEC. Read the 6-K on sec.gov
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Smith & Nephew plc (SNN) do?
Smith & Nephew sells implants and consumables into the operating room and the wound clinic, and it runs three global business units. Orthopaedics, the largest at $2,437 million of 2025 revenue, covers knee implants, hip implants, other reconstruction and a trauma and extremities line. Sports Medicine & ENT, $1,934 million in 2025, sells arthroscopic repair systems, the REGENETEN bioinductive implant for rotator cuff repair, visualisation and resection hardware, and ear, nose and throat instruments. Advanced Wound Management, $1,793 million, spans foam and antimicrobial dressings, negative pressure wound therapy devices such as PICO and RENASYS, and a bioactives portfolio that includes SANTYL and skin substitutes. Group revenue was $6,164 million in 2025, up 6.1% reported and 5.3% underlying, and the business employs roughly 17,000 people. Around half of sales come from the United States: US revenue was $1,591 million of the $3,097 million booked in the first half of 2026. Emerging markets, where the company grew 10.6% underlying in that half, are the fastest-moving geography and also the source of the China pricing risk described below. The customer is a hospital or a surgical centre, the sale is usually a consumable or an implant rather than a capital item, and revenue is therefore closely tied to elective procedure volumes in the United States, Europe and Japan.
What drives the numbers is the gap between the franchises. Sports Medicine & ENT and Advanced Wound Management earned 23.8% and 24.9% segment trading margins in 2025; Orthopaedics earned 14.9%, and in the first half of 2026 it ran at 13.0%. Orthopaedics has been the fix-it project for four years, first through the 12-Point Plan that ran to the end of 2025 and now under the RISE strategy launched in December 2025, which targets a 6% to 7% organic revenue CAGR and a 9% to 10% trading profit CAGR out to 2028. Trading profit, the company's own preferred profit measure, ran at $1,211 million in 2025 against reported operating profit of $794 million, and the difference is restructuring, acquisition amortisation and legal charges that have recurred every year. The market is paying about 20 times trailing reported earnings and roughly 13 times forward consensus earnings for that mix. The shares slid after management cut 2026 revenue growth guidance from around 6% to around 4% on August 4, touched a 52-week low of ~$26.12, and closed at ~$30.06 on November 20, 2026, down ~8.6% for the year and ~6.0% over twelve months. Trading profit, free cash flow and return guidance survived the August cut but not the November one: with third-quarter revenue of ~$1.55 billion, up 3.4% underlying, the company now expects about 3% underlying growth, ~$1.25 billion of trading profit, ~$750 million of free cash flow and ROIC of about 9%. The same update said talks with Johnson & Johnson about a combination involving DePuy Synthes had ended and that the board is evaluating strategic alternatives for Orthopaedics, with no decision or timeline.
What's driving Smith & Nephew plc (SNN)?
1. Sports Medicine is doing the compounding
Sports Medicine & ENT grew 7.7% underlying in the first half of 2026 to $1,017 million, and 8.6% in the second quarter alone, while the rest of the group was roughly flat. Joint Repair, the largest piece at $574 million, grew 10.3% underlying on REGENETEN and the knee repair portfolio. Segment trading margin rose 160 basis points to 24.7%, so the growth is arriving with operating leverage rather than at the cost of it. In January 2026 the company paid $390 million in fair value consideration for Integrity Orthopaedics and its Tendon Seam rotator cuff repair technology, comprising $225 million of initial cash and $165 million of discounted milestone payments. Management has said it wants to be the global leader in sports medicine, and this is the franchise where the RISE targets are best supported by current trading. The third quarter kept the pace: Sports Medicine & ENT grew 7.9% underlying, joint repair 11.2%, with double-digit US growth across all three segments. Product launches have continued too: the CARTIHEAL AGILI-C cartilage repair implant launched across key European markets in October 2026.
2. Orthopaedics margin ahead of Orthopaedics revenue
Orthopaedics revenue was $1,213 million in the first half of 2026, down 0.1% underlying, with US knee implants falling 7.2% in the second quarter. The stated causes are deliberate portfolio rationalisation, capital discipline on instrument sets, and a market shift toward cementless knees that the company was late to serve. Margin has moved anyway: segment trading profit rose 36.9% in 2025 to $363 million, and the first-half 2026 margin ticked up 30 basis points to 13.0% despite an inventory revaluation headwind. The revenue answer is meant to arrive through product. LEGION MS now accounts for almost 20% of the LEGION mix, LEGION CONCELOC cementless is growing double digits, and the kinematic LANDMARK Knee System is the launch management points at for late 2026 and 2027. In the third quarter Orthopaedics grew 2.5% underlying, with hips and knees strong outside the US and still weak inside it; management blames US knee losses on business lost in earlier periods, including surgeon retirements, and on cementless knees, now nearly 40% of the US market, where its own portfolio is only about 10% cementless. The cementless LANDMARK knee has FDA approval and the cemented version is expected in the second quarter of 2027. Until those ship at scale, the franchise is a margin story attached to a slow revenue line. In trauma, the EVOS PELVIC system launched at the end of September 2026. The board is now evaluating strategic alternatives for the whole Orthopaedics business after talks with Johnson & Johnson about combining it with DePuy Synthes ended, and has given no decision or timeline.
3. Efficiency savings could not absorb a second cut
On August 4, 2026 the company cut expected full-year revenue growth from around 6% to around 4%, and at first left trading profit, free cash flow and return on invested capital guidance unchanged, at roughly $1.3 billion of trading profit after the Integrity acquisition, about $800 million of free cash flow, and adjusted ROIC above 10% excluding Integrity. The offset was $50 million of additional efficiency savings identified during the half, taking planned 2026 savings to around $200 million, and tariffs were expected to be broadly neutral to trading profit net of refunds. Hitting that plan required second-half revenue growth of 5.0% to 5.5%. The third quarter delivered 3.4% underlying, an acceleration from the second quarter but short of that pace, so in November the company cut again: about 3% underlying revenue growth, ~$1.25 billion of trading profit, ~$750 million of free cash flow and ROIC of about 9%. The skin substitute headwind is still expected toward the upper end of its $20 million to $40 million range. Guidance for 2027 is due with fourth-quarter results. Analyst consensus for full-year 2026 sits near $2.15 per ADS on ~$6.41 billion of revenue, and for 2027 near $2.37 on ~$6.72 billion.
4. An activist holder that keeps adding
Cevian Capital filed a Schedule 13D on Smith & Nephew in July 2024, the activist form rather than the passive one. It held 5.02% at the company's February 2026 disclosure date and 119,179,419 ordinary shares, or 14.18% of the 840,515,838 outstanding, by the July 27, 2026 amendment, at a cost of about $1.67 billion. Press reporting has it above 14.2% in early August. Investors including Cevian have publicly pressed the board to consider separating the businesses. In November 2026 the company confirmed that talks with Johnson & Johnson about a combination involving DePuy Synthes had ended and that it is evaluating strategic alternatives for Orthopaedics; no separation, break-up or sale has been announced. Management's capital response so far has been cash returns: a $500 million buyback announced in May 2026 with $250 million completed by the end of the third quarter and Merrill Lynch retained in November to execute a further $250 million tranche, following a $500 million programme run in the second half of 2025, plus an interim dividend raised 4.0% to 15.6 cents.
What are the risks to Smith & Nephew plc (SNN)?
The clearest risk is that US Orthopaedics does not turn. Knee implants fell 7.2% in the US in the second quarter of 2026, US hips and knees were still weak in the third, and the fix depends on launches, principally LANDMARK and wider LEGION MS set deployment, that mostly land in 2027. Launches slip, surgeons switch slowly, and a competitor with four times the revenue can out-spend the response. Advanced Wound Bioactives is the second pressure point: revenue fell 8.1% underlying in the first half and 8.8% in the third quarter after the January 2026 US reimbursement reset on skin substitutes, and the full-year headwind is now expected toward the upper end of a $20 million to $40 million range. China is a third. Volume-based procurement has already compressed sports medicine pricing, the ENT tender process has been delayed into the second half of 2026, and the company has been running down channel inventory ahead of it, so the reported growth in that market is not a clean read on demand. Execution risk sits on top of all of it: the company has now cut 2026 guidance twice, in August and November, and the second cut reached trading profit, free cash flow and ROIC as well as revenue. The strategic review of Orthopaedics adds uncertainty in both directions, since the Johnson & Johnson talks ended without a deal. RBC cut its price target to GBP 11.50 from GBP 12.50 in November. There is a governance gap as well. CFO John Rogers resigned on August 19, 2026 and left on September 30; Pierre Palassian is interim CFO while the search continues. Cevian's 14.2% position could force portfolio action or leave a large overhang if the thesis is abandoned. Legacy metal-on-metal hip claims still carry provisions, adjusted net debt to EBITDA was 1.8 times at the half, and $350 million of corporate bonds plus $140 million of private placement debt fall due in the first half of 2027.
What is the Smith & Nephew plc (SNN) forecast?
5 analysts publish price targets on SNN, averaging $33.19 as of November 2026, or +11.3% against the $29.83 share price on November 20, 2026. The published targets run from $30.90 to $38.00, a narrow spread, and the ratings split 1 buy, 5 hold, 0 sell. Over the last six months there have been 0 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full SNN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is SNN a buy or a sell?
We give no verdict on Smith & Nephew plc. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Sports Medicine is doing the compounding. Sports Medicine & ENT grew 7.7% underlying in the first half of 2026 to $1,017 million, and 8.6% in the second quarter alone, while the rest of the group was roughly flat. The most optimistic published target, $38.00, assumes this works close to its best case.
The case against. The clearest risk is that US Orthopaedics does not turn. The most pessimistic target, $30.90, is roughly what SNN is worth if this bites instead.
Read the full bull and bear case on SNN, including what would have to change to break either one. Walnut is not an investment adviser.
Has Smith & Nephew plc (SNN) split its stock?
No. Smith & Nephew plc (SNN) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Smith & Nephew plc (SNN) valued?
Market cap, P/E and dividend yield at today's price are in the SNN key stats above. The business figures below come from Smith & Nephew plc's reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$6.30 billion for the twelve months to June 27, 2026 (the latest period with full financial statements), against $6,164 million in 2025, up 6.1% reported and 5.3% underlying, and $5,810 million in 2024. First-half 2026 growth was 4.6% reported but only 2.3% underlying. Third-quarter 2026 revenue was ~$1.55 billion, up 3.4% on both underlying and reported bases. Everything here is reported in US dollars, the company's actual reporting currency, so no conversion from sterling is involved.
- Earnings and adjusted earnings: Attributable profit of ~$635 million on a trailing basis, giving roughly $1.47 per ADS at the two-for-one ratio (~73-74 cents per ordinary share). Full-year 2025 EPS was 72.1 cents per ordinary share on operating profit of $794 million. The company's preferred measure runs well above that: trading profit was $1,211 million in 2025 (19.7% margin), with adjusted EPS of 102.0 cents per ordinary share, about $2.04 per ADS. 2026 trading profit guidance is now ~$1.25 billion. The gap between operating and trading profit, roughly $440 million in 2025, is restructuring, acquisition amortisation and legal items.
- Franchise growth and margins: 2025 segment trading margins were 14.9% for Orthopaedics, 23.8% for Sports Medicine & ENT and 24.9% for Advanced Wound Management. Third-quarter 2026 underlying growth was Orthopaedics +2.5%, Sports Medicine & ENT +7.9% (joint repair +11.2%) and Advanced Wound Management -0.2% (Bioactives -8.8%). By geography, the US grew 3%, other established markets 3.2% and emerging markets 4.8%.
- Cash flow and balance sheet: Free cash flow of ~$1.06 billion on Yahoo Finance's trailing basis and $836 million in 2025; 2026 guidance is now ~$750 million, down from ~$800 million. Total debt is ~$3.78 billion against ~$754 million of cash, and adjusted net debt to EBITDA was 1.8 times at the half. $350 million of corporate bonds and $140 million of private placement notes fall due in the first half of 2027.
- Market pricing: The ADS closed at ~$30.06 on November 20, 2026, against a 52-week range of ~$26.12 to ~$37.09, down ~8.6% year to date and ~6.0% over one year. Market capitalisation is ~$12.6 billion. The dividend rate of ~$0.79 per ADS is a yield of ~2.7%, with a payout ratio near 53% of trailing earnings.
- Guidance and 2028 targets: 2026 guidance was cut twice: in August revenue growth went to around 4% from around 6%, and in November to about 3% underlying, with trading profit lowered to ~$1.25 billion from ~$1.3 billion, free cash flow to ~$750 million from ~$800 million and ROIC to about 9%. The RISE strategy of December 2025 targets a 6% to 7% organic revenue CAGR and 9% to 10% trading profit CAGR through 2028, against 2025 adjusted ROIC of 8.3%. 2027 guidance comes with fourth-quarter results.
As of November 2026: The multiple sits well below the large-cap orthopaedic peer group, and the reason is visible in the segment table more than in any accounting subtlety: the largest franchise earns the lowest margin and grows slowest. At ~13 times forward consensus earnings in November 2026, after two guidance cuts and the end of talks with Johnson & Johnson, investors are paying for the RISE targets to close that gap, or for the Orthopaedics strategic review to force the issue on portfolio structure. Five covering analysts carry a mean target of ~$33.19 and a hold rating.
Who competes with Smith & Nephew plc (SNN)?
Large-cap orthopaedic implant makers
Stryker, Zimmer Biomet, Johnson & Johnson MedTech's DePuy Synthes and Medtronic are the direct competition in hips, knees, trauma and extremities. Stryker carries roughly four times Smith & Nephew's revenue and has spent heavily on robotics with Mako, while Zimmer Biomet is the closest thing to a reconstruction pure play. Scale matters here because instrument sets, surgeon training and hospital contracting all reward the incumbent. Smith & Nephew's US knee decline in 2026 is share moving to these companies as the market shifts toward cementless implants.
Sports medicine and arthroscopy
Arthrex, which is privately held and does not disclose figures, is the reference competitor in sports medicine, alongside Stryker's sports medicine business, CONMED and Enovis. This is the arena where Smith & Nephew is winning: joint repair grew 10.3% underlying in the first half of 2026, and REGENETEN and the Integrity Orthopaedics Tendon Seam technology are both aimed at rotator cuff repair, the highest-value procedure in the category. Competition here turns on procedure-level innovation and surgeon relationships rather than hospital tender pricing, one reason margins run several points above Orthopaedics.
Advanced wound care and skin substitutes
Convatec, privately held Molnlycke, Solventum (the 3M health care spinoff), Coloplast and Integra LifeSciences compete across dressings and negative pressure wound therapy, while Organogenesis and MiMedx are the reference names in the skin substitutes market that reset on US reimbursement in January 2026. The wound business was the group's highest-margin franchise at 24.9% in 2025, but the bioactives line inside it carries the most policy-exposed revenue the company has.
What stocks are similar to Smith & Nephew plc (SNN)?
Other names that sit close to SNN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Smith & Nephew plc (SNN)
There are three common ways to get SNN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so SNN sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where SNN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Smith & Nephew plc (SNN)
As of November 2026, SNN is a three-franchise medtech company where Sports Medicine compounds, wound care absorbs a US reimbursement reset, and Orthopaedics is fixing its margin faster than its revenue, while the board weighs what to do with that franchise after talks with Johnson & Johnson ended. The ADS sits at ~$30, down ~9% this year after a second 2026 guidance cut to ~3% underlying growth and ~$1.25 billion of trading profit, while Cevian Capital, holding about 14.2% on an activist 13D at its last disclosed filing, presses for change.
More on Smith & Nephew plc (SNN)
Whether SNN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is SNN a buy or a sell?, and where the stock could go from here in the SNN stock forecast.
For income investors, whether SNN pays a dividend and how the payout looks is covered in does SNN pay a dividend? And to weigh SNN against a peer, read the full side-by-side comparisons: SNN vs SYK and SNN vs ZBH.
Wondering how SNN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Smith & Nephew plc
Ask Walnut's AI anything about SNN and see how it fits what you own.
FAQ
What does Smith & Nephew do?
+
Smith & Nephew is a medical technology company that makes products used in surgery and wound care, organised into three global business units. Orthopaedics supplies knee and hip implants, other reconstruction products, and trauma and extremities hardware, and generated $2,437 million of revenue in 2025. Sports Medicine & ENT sells arthroscopic repair implants and instruments, visualisation and tissue resection equipment, and ear, nose and throat devices, at $1,934 million. Advanced Wound Management covers foam and antimicrobial dressings, negative pressure wound therapy systems including PICO and RENASYS, and a bioactives range that includes SANTYL and skin substitutes, at $1,793 million. Group revenue was $6,164 million in 2025 and roughly $6.30 billion for the twelve months to June 27, 2026; third-quarter 2026 revenue was ~$1.55 billion. The company employs about 17,000 people and is headquartered in Watford, England.
Why did SNN stock drop in 2026?
+
The stock spent 2026 giving back a 2025 gain of 28%, fell to a 52-week low of ~$26.12 after the August results, and closed at ~$30.06 on November 20, 2026, down ~8.6% for the year and below the ~$37.09 52-week high. The first cause was the August 4, 2026 half-year results, at which management cut full-year revenue growth guidance from around 6% to around 4%. First-half underlying growth was 2.3%, US knee implants fell 7.2% in the second quarter, and Advanced Wound Bioactives revenue fell 8.1% underlying after a US reimbursement change on skin substitutes took effect in January. Profit guidance held at first, helped by an extra $50 million of cost savings, but the November third-quarter update cut it too: about 3% underlying revenue growth, ~$1.25 billion of trading profit, ~$750 million of free cash flow and ROIC of about 9%. The same update said talks with Johnson & Johnson over a DePuy Synthes combination had ended.
Is SNN a good dividend stock?
+
Smith & Nephew pays a dividend twice a year and declares it in US dollars, since dollars are its reporting currency. The 2025 total distribution was 39.1 cents per ordinary share, up 4.3%, which is 78.2 cents per ADS and works out at a yield of roughly 2.7% at the ~$30.06 ADS price of November 20, 2026. The 2026 interim was raised 4.0% to 15.6 cents per ordinary share. Cover is comfortable on the company's own numbers: 2025 free cash flow of $836 million against a distribution costing roughly $340 million, alongside two separate $500 million buyback programmes, one executed in the second half of 2025 and one announced in May 2026 with $250 million completed by the end of the third quarter. 2026 free cash flow guidance is now ~$750 million. Growth in the payout has run in the low single digits, so the appeal is stability rather than escalation. UK holders receive payments converted to sterling.
Who are Smith & Nephew's competitors?
+
In orthopaedics the competition is Stryker, Zimmer Biomet, Johnson & Johnson MedTech's DePuy Synthes and Medtronic, all of which are larger in that category and several of which have invested more heavily in surgical robotics. In sports medicine the reference competitor is privately held Arthrex, alongside Stryker, CONMED and Enovis. In wound care it is Convatec, privately held Molnlycke, Solventum, Coloplast and Integra LifeSciences, with Organogenesis and MiMedx in skin substitutes specifically. The competitive position differs sharply by franchise, and the segment margins show it: Sports Medicine & ENT and Advanced Wound Management earned 23.8% and 24.9% trading margins in 2025, while Orthopaedics earned 14.9%. Smith & Nephew is a strong number two or three in sports medicine and wound care, and a distant fourth in large-joint reconstruction.
What is Cevian Capital's stake in Smith & Nephew?
+
Cevian Capital II GP Limited filed a Schedule 13D on Smith & Nephew in July 2024, the form used when a holder intends to influence control rather than hold passively. Its most recent amendment, filed July 27, 2026, disclosed 119,179,419 ordinary shares, or 14.18% of the 840,515,838 shares outstanding as of July 23, 2026, bought for aggregate consideration of about $1.67 billion. Press reports put the holding above 14.2% in early August 2026. That makes Cevian the largest shareholder, ahead of BlackRock, which held 7.17% at the company's February 2026 disclosure date. Investors including Cevian have publicly urged the board to consider separating the businesses. In November 2026 the company said talks with Johnson & Johnson about a combination involving DePuy Synthes had ended and that it is evaluating strategic alternatives for Orthopaedics. No separation, break-up, sale or take-private has been announced, and the RISE strategy launched in December 2025 remains the stated plan.
Does Smith & Nephew report in pounds or dollars?
+
US dollars. Smith & Nephew is incorporated in England and Wales, headquartered in Watford, and primarily listed in London, but it has reported its results in US dollars for years, and its ordinary shares carry a par value of 20 US cents each. Every figure in its annual report and interim statements, including revenue of $6,164 million for 2025 and $3,097 million for the first half of 2026, is a dollar figure as filed and not a conversion. Dividends are declared in dollars too. This matters because a screener that flags SNN as a UK company will sometimes prompt an unnecessary currency adjustment, which produces a revenue or earnings figure that is wrong by 25% or more. Currency still moves reported growth, because roughly half of sales are outside the US: the first half of 2026 carried a 230 basis point foreign exchange tailwind.
How does China volume-based procurement affect Smith & Nephew?
+
China's volume-based procurement programme runs national tenders that cut device prices in exchange for volume commitments, and Smith & Nephew has been through several rounds. The sports medicine round that began in May 2024 compressed pricing enough that Sports Medicine & ENT's 2025 trading margin fell 20 basis points to 23.8% despite revenue growth of 5.2% underlying. The ENT tender has been delayed and is now expected in the second half of 2026, and the company has been deliberately reducing channel inventory ahead of it, which is why ENT revenue fell 5.4% underlying in the first half of 2026 while every other region grew. Management expects China to be broadly neutral to full-year growth in 2026. Emerging markets in aggregate grew 10.6% underlying in the first half, with China contributing double-digit growth in the second quarter. In the third quarter emerging markets slowed to 4.8% underlying, and group growth excluding China was 4% against 3.4% including it.
How did Smith & Nephew do in its latest reported period?
+
In the third quarter of 2026, reported in early November, revenue was ~$1.55 billion, up 3.4% on both underlying and reported bases and faster than the second quarter. Sports Medicine & ENT grew 7.9% underlying, Orthopaedics 2.5% and Advanced Wound Management was down 0.2%, with Bioactives off 8.8%. Management cut full-year guidance to about 3% underlying revenue growth, ~$1.25 billion of trading profit and ~$750 million of free cash flow, and said talks with Johnson & Johnson over DePuy Synthes had ended. That followed a first half, reported on August 4, with revenue of $3,097 million, up 2.3% underlying, and the earlier cut to around 4% growth.
How has SNN stock performed in 2026?
+
As of the November 20, 2026 close at ~$30.06, the SNN ADS was down ~8.6% year to date and ~6.0% over one year, up ~2.9% over three months and down ~2.5% over the past month. Its 52-week range is ~$26.12 to ~$37.09, and the mean target among five analysts is ~$33.19. Walnut is not an investment adviser and does not tell anyone whether to buy or sell SNN.
What happened with Smith & Nephew and Johnson & Johnson?
+
In its third-quarter 2026 update, Smith & Nephew said talks with Johnson & Johnson about a combination involving DePuy Synthes, J&J's orthopaedics business, had ended. The company is evaluating strategic alternatives for its own Orthopaedics unit, its largest and lowest-margin franchise, and has given no decision or timeline. Cevian Capital, which holds about 14.2% of the shares, has pushed the board to consider separating the businesses.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Smith & Nephew plc's investor relations page or your broker before making investment decisions.